巴西痴呆症的成本
Fabiana Araújo Figueiredo da Mata1, Ari Alex Ramos1, Laiss Bertola1
1Responsabilidade Social, Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil. Departamento de Psiquiatria, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
概括
在巴西,家庭护理人员承担了超过73%的痴呆成本. 这凸显了迫切需要更好地支持痴呆症患者及其家属的战略,考虑到痴呆症患病率的上升.
科学领域:
- 公共卫生 公共卫生
- 卫生经济学 卫生经济学
- 老年学是一门学科.
背景情况:
- 巴西的痴呆症患病率正在上升,需要紧急规划卫生和社会系统.
- 了解与痴呆相关的成本对于制定有效的支持策略至关重要.
- 这项研究解决了巴西对痴呆症成本研究的关键需求.
研究的目的:
- 估计与巴西痴呆症相关的直接和间接成本.
- 从社会和医疗保健系统的角度分析痴呆的成本.
主要方法:
- 采用了疾病成本方法.
- 数据是从巴西国家痴呆症报告 (ReNaDe) 中通过家庭采访收集的.
- 公共的国家数据库被用来收集有关医疗服务利用率和相关成本的信息.
主要成果:
- 随着疾病的进展,每个患者的月度痴呆成本随着疾病的进展而升级:843.04美元 (初级),1317.81美元 (中级) 和1576.15美元 (高级).
- 间接成本占有很大一部分,占痴呆症相关总费用的至少73%.
- 痴呆症的国家医疗保健支出最高的是在该综合征的中间阶段发生的.
结论:
- 家庭护理人员承担着相当大的负担,至少占巴西痴呆症相关医疗成本的73%.
- 这些发现强调了对痴呆症患者及其家庭护理人员加强支持系统的迫切需要.
- 政策干预应侧重于减轻管理痴呆症护理的家庭的财务和社会影响.
相关概念视频
Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Aging
37
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
37
Intellectual Disability
42
Intellectual disability (ID) is a neurodevelopmental condition characterized by deficits in intellectual and adaptive functioning that manifest during the developmental period. This condition encompasses challenges in reasoning, memory, problem-solving, and learning, accompanied by impairments in everyday life skills, such as communication, self-care, and social interactions. Intellectual disability affects approximately 1% of the population in the United States, impacting an estimated 5...
42
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482


